ArticleJournal of inflammation research2025
Diagnostic Value and Regulatory Mechanism of miR-322-5p in Coronary Heart Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The diagnostic value and mechanistic role of miR-20b-5p in premature coronary artery disease.Irish journal of medical science · 2026Article
- Complement Components C1r and C8 Serve as Potential Inflammatory Biomarkers for Coronary Heart Disease Severity: The Mediating Role of C-Reactive Protein.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary heart disease (CHD) is a heart condition caused by narrowed or blocked coronary arteries. The miR-322-5p is closely related to inflammation and vascular diseases, yet its role in CHD remains unknown. Objective: This study focused on investigating the clinical significance of miR-322-5p and its regulatory mechanism in CHD. Materials and Methods: This study enrolled 160 CHD patients and 130 healthy individuals. The expression of miR-322-5p and TRAF6 was measured by RT-qPCR. The correlation between miR-322-5p and CHD was evaluated via Pearson correlation analysis. The clinical predictive performance of miR-322-5p was assessed by ROC analysis. Cell viability was assessed using the CCK-8 assay while apoptosis was analyzed by flow cytometry. Inflammatory cytokine levels were determined by ELISA. Results: MiR-322-5p was significantly downregulated in patients with CHD and exhibited high diagnostic accuracy for CHD with an AUC of 0.882. The declined miR-322-5p was negatively correlated with Gensini score (r = -0.611) and CRP (r = -0.646), but positively associated with HDL-C (r = 0.598). Although miR-322-5p was reduced under pathological conditions, its upregulation enhanced cell viability and inhibited both apoptosis and inflammatory factors. TRAF6, a direct target of miR-322-5p, was negatively regulated by miR-322-5p (r = -0.683), and high levels of TRAF6 aggravated CHD. Conclusion: The declined miR-322-5p in CHD presented high diagnostic value. Reduced miR-322-5p exacerbated the CHD by inhibiting cell viability, enhancing apoptosis and inflammation through negatively regulating the TRAF6.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.